FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications FDA, February 20, 2020

Hot Topics of the Day|PHGKB


Last Posted: Feb 23, 2020

---

• FDA Announces Collaborative Review of Scientific Evidence to Support Associations Between Genetic Information and Specific Medications
  FDA, February 20, 2020
• Table of Pharmacogenetic Associations
  FDA, February 20, 2020
• Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice.
  Anandi Prathima et al. The pharmacogenomics journal 2020 Feb
• Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
  Limdi Nita A et al. The pharmacogenomics journal 2020 Feb
• Pain Management Using Clinical Pharmacy Assessments With and Without Pharmacogenomics in an Oncology Palliative Medicine Clinic.
  Patel Jai N et al. JCO oncology practice 2020 Feb 16(2) e166-e174
• [Perspectives of the use of pharmacogenetic tests in neurology and psychiatry].
  Kostyuk G P et al. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2019 119(9) 131-135
• Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data.
  Roche-Lima Abiel et al. Frontiers in pharmacology 2019 101550
• Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.
  Cornett Elyse M et al. Current oncology reports 2020 Feb 22(2) 18
• Use of pharmacogenetic data to guide individualized opioid prescribing after surgery.
  Rocco Raffaele et al. Surgery 2019 166(4) 476-482
• Pharmacogenomics: An evolving clinical tool for precision medicine.
  Hockings Jennifer K et al. Cleveland Clinic journal of medicine 2020 Feb 87(2) 91-99

more